Drug Approval | December 30, 2024
Cenexi's Fontenay manufacturing facility receives 10 observations in ANSM inspection
Cenexi is committed to working closely with the ANSM to address the observations
Cenexi is committed to working closely with the ANSM to address the observations
Prior to this, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
Subscribe To Our Newsletter & Stay Updated
